Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). [electronic resource]
- Transplant infectious disease : an official journal of the Transplantation Society Aug 2020
- e13286 p. digital
Publication Type: Case Reports; Journal Article
1399-3062
10.1111/tid.13286 doi
Adult Antiviral Agents--adverse effects Betacoronavirus C-Reactive Protein--immunology COVID-19 Ciliopathies--complications Cobicistat--therapeutic use Common Cold--etiology Coronavirus Infections--complications Cough--etiology Cytochrome P-450 CYP3A Inhibitors--adverse effects Darunavir--therapeutic use Deprescriptions Drug Combinations Drug Interactions Enzyme Inhibitors--therapeutic use Fatigue--etiology Female Glucocorticoids--therapeutic use Graft Rejection--prevention & control Humans Hydroxychloroquine--therapeutic use Immunocompromised Host--immunology Immunosuppressive Agents--adverse effects Interleukin-10--immunology Interleukin-1beta--immunology Interleukin-6--immunology Interleukin-8--immunology Kidney Diseases, Cystic--complications Kidney Failure, Chronic--etiology Kidney Transplantation Leber Congenital Amaurosis--complications Lopinavir--adverse effects Methylprednisolone--therapeutic use Optic Atrophies, Hereditary--complications Pandemics Pneumonia, Viral--complications Ritonavir--adverse effects SARS-CoV-2 Severity of Illness Index Tacrolimus--adverse effects COVID-19 Drug Treatment